JP4851348B2 - 抗Ａβ抗体 - Google Patents

抗Ａβ抗体 Download PDF

Info

Publication number
JP4851348B2
JP4851348B2 JP2006554230A JP2006554230A JP4851348B2 JP 4851348 B2 JP4851348 B2 JP 4851348B2 JP 2006554230 A JP2006554230 A JP 2006554230A JP 2006554230 A JP2006554230 A JP 2006554230A JP 4851348 B2 JP4851348 B2 JP 4851348B2
Authority
JP
Japan
Prior art keywords
antibody
peptide
gel
antibodies
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006554230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500279A5 (https=
JP2008500279A (ja
Inventor
ロナルド・ブラッドリー・デマットス
ウマ・クチボトラ
シュウ−チウン・ヤン
ドン・ビー・マックルーア
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2008500279A publication Critical patent/JP2008500279A/ja
Publication of JP2008500279A5 publication Critical patent/JP2008500279A5/ja
Application granted granted Critical
Publication of JP4851348B2 publication Critical patent/JP4851348B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2006554230A 2004-02-23 2005-02-17 抗Ａβ抗体 Expired - Fee Related JP4851348B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
US60/546,764 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (3)

Publication Number Publication Date
JP2008500279A JP2008500279A (ja) 2008-01-10
JP2008500279A5 JP2008500279A5 (https=) 2008-03-06
JP4851348B2 true JP4851348B2 (ja) 2012-01-11

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006554230A Expired - Fee Related JP4851348B2 (ja) 2004-02-23 2005-02-17 抗Ａβ抗体

Country Status (20)

Country Link
US (1) US20070190046A1 (https=)
EP (1) EP1720909B1 (https=)
JP (1) JP4851348B2 (https=)
KR (2) KR100889430B1 (https=)
CN (1) CN1922209B (https=)
AT (1) ATE534667T1 (https=)
AU (1) AU2005217596B2 (https=)
BR (1) BRPI0507856A (https=)
CA (1) CA2556436C (https=)
CY (1) CY1112162T1 (https=)
DK (1) DK1720909T3 (https=)
EA (1) EA009872B1 (https=)
ES (1) ES2375627T3 (https=)
IL (1) IL177611A (https=)
NO (1) NO20064239L (https=)
PL (1) PL1720909T3 (https=)
PT (1) PT1720909E (https=)
SI (1) SI1720909T1 (https=)
UA (1) UA93181C2 (https=)
WO (1) WO2005082939A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP1959996A2 (en) 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
US20110110942A1 (en) 2009-11-12 2011-05-12 Genentech, Inc. Method of promoting dendritic spine density
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
US20210355138A1 (en) * 2016-08-11 2021-11-18 Eli Lilly And Company Aminothiazinies and their use as bace1 inhibitors
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001232A3 (en) 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies

Also Published As

Publication number Publication date
CN1922209B (zh) 2012-09-05
AU2005217596A1 (en) 2005-09-09
CA2556436A1 (en) 2005-09-09
KR20060126785A (ko) 2006-12-08
PT1720909E (pt) 2011-12-23
US20070190046A1 (en) 2007-08-16
DK1720909T3 (da) 2012-01-30
JP2008500279A (ja) 2008-01-10
CY1112162T1 (el) 2015-12-09
EP1720909A2 (en) 2006-11-15
WO2005082939A2 (en) 2005-09-09
EA200601545A1 (ru) 2007-02-27
WO2005082939A3 (en) 2005-10-27
KR20090005410A (ko) 2009-01-13
IL177611A (en) 2013-05-30
EA009872B1 (ru) 2008-04-28
CA2556436C (en) 2014-04-01
EP1720909B1 (en) 2011-11-23
KR100889430B1 (ko) 2009-03-23
ES2375627T3 (es) 2012-03-02
AU2005217596B2 (en) 2012-01-19
PL1720909T3 (pl) 2012-04-30
SI1720909T1 (sl) 2012-01-31
NO20064239L (no) 2006-11-20
UA93181C2 (ru) 2011-01-25
ATE534667T1 (de) 2011-12-15
CN1922209A (zh) 2007-02-28
IL177611A0 (en) 2006-12-10
BRPI0507856A (pt) 2007-07-10

Similar Documents

Publication Publication Date Title
JP4851348B2 (ja) 抗Ａβ抗体
JP7579589B2 (ja) Ｒａｎタンパク質関連神経学的疾患を処置するための方法
JP5475994B2 (ja) 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
JP2010511386A (ja) 新規Ａβ配座異性体選択的抗Ａβグロブロマーモノクローナル抗体
JP7204235B2 (ja) 活性型α－シヌクレインに結合する抗体
CN101965365A (zh) 能够特异性结合Aβ寡聚体的抗体及其应用
JP2019507107A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用
CN102936287A (zh) 能够特异性结合Aβ 寡聚体的抗体及其应用
CA2819679A1 (en) Compositions and methods for treating amyloid plaque associated symptoms
WO2023206609A1 (zh) 针对p-tau 217的抗体及其用途
WO2021012082A1 (zh) β—淀粉样蛋白环状核糖核酸、多肽及其应用
MXPA06009560A (en) Anti-abeta antibody
US20250353904A1 (en) Preventative Agent or Therapeutic Agent for Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Spinocerebellar Ataxia, Aging-Related Degenerative or Neurological Disease, Brain Aging, or Diseases Associated With Brain Aging
DK2289909T3 (en) The screening method, method of purification of non-diffusing alpha-beta oligomers selective antibodies to said non-diffunderingsdygtige alpha-beta oligomers and a method of producing said antibodies
US20240025985A1 (en) Agent for Preventing or Treating Frontotemporal Lobar Degeneration
HK40125870A (zh) 肌萎缩侧索硬化症、帕金森病、亨廷顿病、脊髓小脑性共济失调、与老化有关的变性疾病或神经疾病、脑老化、或者伴有脑老化的疾病的预防剂或治疗剂
WO2024101345A1 (ja) 異常タンパク質の凝集体蓄積が関与する疾患の予防又は治療剤
WO2022060236A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110607

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110608

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111020

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141028

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees